ACKR1 genetic testing should be offered before starting clozapine treatment
- 7 January 2026
- journal article
- perspective
- Published by Springer Nature in Nature Mental Health
- p. 1-12
Abstract
No abstract availableKeywords
This publication has 67 references indexed in Scilit:
- FDA Eliminates the Clozapine REMS—What Comes Next?JAMA Psychiatry, 2025
- Clozapine and neutrophil response in patients of African descent: A six-month, multinational, prospective, open-label clinical trialSchizophrenia Research, 2023
- Prevention of suicide by clozapine in mental disorders: systematic reviewEuropean Neuropsychopharmacology, 2023
- Clozapine Is Severely Underused in Parkinson's Disease PatientsMovement Disorders Clinical Practice, 2022
- Evaluation of the Cost-effectiveness of Services for Schizophrenia in the UK Across the Entire Care Pathway in a Single Whole-Disease ModelJAMA Network Open, 2020
- Association With Hospitalization and All-Cause Discontinuation Among Patients With Schizophrenia on Clozapine vs Other Oral Second-Generation AntipsychoticsJAMA Psychiatry, 2019
- Benign ethnic neutropeniaBlood Reviews, 2019
- Clozapine for Treatment-Resistant Schizophrenia: Still the Gold Standard?CNS Drugs, 2017
- Relapse following clozapine withdrawal: effect of neuroleptic drugs and cyproheptadinePsychopharmacology, 1996
- Clozapine for the Treatment-Resistant SchizophrenicArchives of General Psychiatry, 1988